<DOC>
	<DOCNO>NCT00375791</DOCNO>
	<brief_summary>This phase 2 study perifosine patient multiple myeloma . Patients receive perifosine 150 mg bedtime ( qhs ) daily . Patients assess serum and/or urine-electrophoresis least every 3 week .</brief_summary>
	<brief_title>Efficacy Perifosine Alone Combination With Dexamethasone Patients With Multiple Myeloma</brief_title>
	<detailed_description>Treatment : Patients take three 50 mg tablet perifosine qhs daily food . All patient continue therapy unless disease progression document two occasion least 1 week apart . Progressing patient dexamethasone 20 mg twice per week add perifosine . Patients experience toxicity may continue treatment dos delay reduce . Evaluations : Serum and/or urine-electrophoresis evaluated progression response 3 week interval . This study enroll total 64 patient .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>Major criterion : 1 . Plasmacytomas tissue biopsy . 2 . Bone marrow plasmacytosis ( &gt; 30 % plasma cell ) . 3 . Monoclonal immunoglobulin spike serum electrophoresis immunoglobulin G ( IgG ) &gt; 3.5 g/dL immunoglobulin A ( IgA ) &gt; 2.0 g/dL ; kappa lambda light chain excretion &gt; 1 g/day 24 hour urine protein electrophoresis . Minor criterion : 1 . Bone marrow plasmacytosis ( 10 30 % plasma cell ) 2 . Monoclonal immunoglobulin present less magnitude give major criterion 3 . Lytic bone lesion 4 . Normal immunoglobulin M ( IgM ) &lt; 50 mg/dL , IgA &lt; 100 mg/dL IgG &lt; 600 mg/dL . Any following set criteria confirm diagnosis multiple myeloma : 1 . Any two major criterion . 2 . Major criterion 1 plus minor criterion b , c d. 3 . Major criterion 3 plus minor criterion c. 4 . Minor criterion , b c , b d. 1 . Renal insufficiency ( serum creatinine level &gt; 3 mg/dL ) . 2 . Patients present either ALT AST â‰¥ 2.5 X upper limit normal . 3 . History allergic reaction attribute compound similar chemical biologic composition perifosine ( miltefosine edelfosine ) . 4 . Concomitant therapy medication include corticosteroid ( except indicate medical condition , 100 mg hydrocortisone premedication administration certain medication blood product ) chemotherapy may active myeloma , therapy chemotherapy within 3 week prior Day 1 . Nitrosoureas must discontinue 6 week prior Day 1 . 5 . Subjects hemoglobin &lt; 8.0 g/dL . 6 . Any condition , include laboratory abnormality , opinion Investigator , place subject unacceptable risk he/she participate study . 7 . Women childbearing potential ( WCBP ) pregnant , breastfeed men woman use adequate contraception exclude . 8 . Plasma cell leukemia .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Relapsed Multiple Myeloma</keyword>
	<keyword>Refractory Multiple Myeloma</keyword>
</DOC>